Coloplast A/S (OTCPK:CLPBF) Q4 2023 Earnings Conference Call November 9, 2023 5:00 AM ETCompany ParticipantsKristian Villumsen - President and Chief…

The following slide deck was published by Coloplast A/S in conjunction with their 2023 Q4 earnings call.

By Ankika Biswas (Reuters) -European shares rose on Thursday, boosted by AstraZeneca and Adyen on strong earnings, while markets awaited the Federal Reserve Chair’s remarks on the monetary policy outlook after European Central Bank officials played down market bets around rate cuts. The pan-European STOXX 600 was up 0.2% by 0904 GMT after touching a three-week high intraday in the prior session. Markets are once again bracing for Powell’s remarks, scheduled for 1900 GMT, a day after he refrained from commenting on interest rates. “Powell is quite comfortable with the message already sent- rate-hiking cycle has likely come to an end but that talk of cuts is premature,” said Stuart Cole, head macro economist at Equiti Capital. ECB policymakers on Wednesday said further progress is needed to tame inflation, while Vice President Luis de Guindos in an interview on Thursday said it is premature to discuss rate cuts amid lingering risks to the inflation outlook. Bank of England Chief Economist Huw Pill also noted the central bank needed to maintain a restrictive stance for monetary policy, a day after Governor Andrew Bailey pushed back against discussions on rate cuts. “One clear take-away is that nothing is expected until at least the middle of next year; the question is whether it will come late H1/early H2, or late H2,” Equiti’s Cole said.

Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to support the company''s continued growth. The new manufacturin…

Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to support the company’s continued growth.

Coloplast''s recent acquisitions may boost growth but come with noticeable margin dilution in the near term. Find out why CLPBF stock is a Hold.